TCP
SRPT icon

Tourbillon Capital Partners’s Sarepta Therapeutics SRPT Stock Holding History

Tourbillon Capital Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,100,000
Closed -$61.2M – 68
2017
Q4 		$61.2M Buy
1,100,000
+205,000
+23% +$10.9M 2.26% 16
2017
Q3 		$40.6M Buy
895,000
+563,600
+170% +$22.5M 0.98% 31
2017
Q2 		$11.2M Buy
+331,400
New +$10.8M 0.22% 61

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Tourbillon Capital Partners's SRPT Position: Q2 2018 in Review

Tourbillon Capital Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2018, closing a stake of 758,413 shares — an estimated $56.2M sold.

Tourbillon Capital Partners first reported a position in SRPT in Q1 2016 and held it in 8 quarters. The position peaked at $105M in Q3 2016. 317 funds tracked by Wall St. Rank hold SRPT as of Q2 2018.

  • Tourbillon Capital Partners reported no remaining Sarepta Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Tourbillon Capital Partners sold 758,413 Sarepta Therapeutics shares in Q2 2018, an estimated $56.2M.
  • Tourbillon Capital Partners first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 8 quarters.
  • Tourbillon Capital Partners's Sarepta Therapeutics position peaked at $105M in Q3 2016.
  • 317 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2018.

Based on Tourbillon Capital Partners's 13F filing for Q2 2018, filed 14 Aug 2018.